Por

[Juan Gómez Rivas @JGomezRivas]

🚨 New evidence for Active Surveillance in prostate cancer!

Proud to share this large international multicentre validation of the PRECISE scoring system for serial prostate MRI during Active Surveillance, now published in European Radiology.

🌍 22 centres | 1,667 patients | median follow-up 4 years

🔑 Key findings:
• PRECISE 4–5 was associated with a 4.53-fold higher odds of biopsy progression compared with PRECISE 1–3.
• At first follow-up MRI, PRECISE ≥4 achieved an NPV of 85% for GG ≥2 progression.
• An MRI-driven strategy using PRECISE ≥4 to trigger biopsy could potentially avoid 70% of repeat biopsies, although this comes with a risk of missing some GG ≥2 progression—highlighting the need to integrate MRI with other clinical parameters.

💡 Take-home message: PRECISE provides a standardized and clinically meaningful way to interpret MRI changes over time helping identify men who may need re-biopsy or treatment while potentially reducing unnecessary biopsies in those with stable disease.

https://t.co/50gXPHEFzs

#ProstateCancer #ActiveSurveillance #ProstateMRI #PRECISE #Urology

@giga_fra @GGandaglia @VPanebiancoIT @F_Sanguedolce @ArmandoStabile @Fabio_Zattoni @ClaudiaKesch @JPRadtke @JGrummet @veerukasi @mrsprostate

[Enrique Grande @drenriquegrande]

⚡️ On @NatRevUrol - IBCG consensus on clinically actionable biomarkers in bladder cancer across the disease spectrum.

Key recommendations: ctDNA is prognostic after neoadjuvant therapy and radical cystectomy, and predictive for adjuvant immunotherapy benefit. FGFR3 and HER2 should be assessed in locally advanced/metastatic disease.

https://t.co/kjzIASGPAx

#BladderCancer

[UroToday.com @urotoday]

Who’s left behind? Closing the gaps in #BladderCancer progress. Can circulating tumor DNA (ctDNA) transform bladder cancer care? Emerging evidence suggests ctDNA may help detect molecular residual disease, predict recurrence, guide adjuvant therapy, and monitor treatment response earlier than conventional imaging. Learn about the latest data from #BCANTT26 > https://t.co/SO9RlbJuNz @BladderCancerUS @PGrivasMDPhD @koshkin85 @chavarriagaj @JCensits @apolo_andrea

[Adam B. Weiner, MD @Adam_Weiner535]

If a cancer treatment doesn’t meaningfully improve quality-adjusted survival, are we really moving the field forward?

[European Urology Oncology @EurUrolOncol]

➡️ Monday Morning Mention!
➡️ Risk-adapted Omission of Systematic Cores in PI-RADS 3 Lesions Based on Prostate-specific Antigen Density, Biopsy Route, and Targeted Core Number: A Multicentre Cohort Study by Bogdan Adrian Buhas ...Guillaume Ploussard et al
➡️ https://t.co/3B6Calffai

➡️ We thank the authors for trusting EUO with your work!

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[UroToday.com @urotoday]

First-line therapy determines bladder preservation in high-grade #NMIBC. @pcvblack @VanProstateCtr joins @UroDocAsh @UTMDAnderson to discuss bladder-preservation strategies in high-grade nonmuscle-invasive #BladderCancer, covering first-line optimization through second-line options. #WatchNow on UroToday > https://t.co/iDULprEan4

[Yüksel Ürün @DrYukselUrun]

Impressive efficacy. Substantial toxicity.
🧬TALAPRO-3: 3-year rPFS 77% vs 56% (HR 0.48)
Grade ≥3 anemia occurred in 51%.
Should upfront PARP intensification be for all HRR-altered mHSPC?
@neerajaiims @OncoAlert @OpenMedicineHQ @NEJM @APCCC_Lugano

[MSKPhysioJournal @MSKPhysioJnl]

Persistent deep buttock pain? Could it be more than gluteal tendinopathy?
Ischiofemoral impingement (IFI) is an often-overlooked cause of posterior hip and buttock pain, frequently misdiagnosed because of its overlapping presentation with gluteal tendinopathy, proximal hamstring tendinopathy, hip osteoarthritis, and lumbar spine disorders.

This clinical masterclass provides a comprehensive, evidence-informed guide to recognizing and managing IFI, integrating current research with expert clinical experience.

Read the full masterclass here for more deeper insights: https://t.co/IGaSXqriRW
#Ischiofemoral impingement #Buttock pain #Buttocks #Hip

[UroToday.com @urotoday]

Operationalizing ctDNA in #BladderCancer clinical trials. Presentation by @mouwlab @DanaFarber, @alantanmd @VUMChealth. and Peter Schiller. #BCANTT26 written coverage by @chavarriagaj @PSH_Urology on UroToday > https://t.co/DFFVS8pj6m @DrJohnSfakianos @LauraBukavinaMD @BladderCancerUS

[UroToday.com @urotoday]

#MIBC: How to manage the bladder after EVP. presentation by @DrRosenbergMSK @MSKCancerCenter, @UroDocAsh @UTMDAnderson, @SimaPorten @UCSFCancer, and @jdtreffert. #BCANTT26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/pUdH72vHpT @koshkin85 @JoshMeeks @BladderCancerUS

[Karine Tawagi MD @DrKarineTawagi]

📣 FDA approval of Pluvicto triplet vs ADT/ARPI for mCSPC (APMS) #PSMAddition

✔️ rPFS: HR 0.72
✔️ time to mCRPC: HR 0.70
✔️ similar QoL

❓OS data immature
❗️ wide eligibility criteria for ➕ PSMA
❓vs chemo or other triplets (PARP/AKT)

Exciting year for GU onc!

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 PARP-i in metastatic hormone-sensitive #ProstateCancer🚨

📜#TALAPRO3 out in @NEJM

In HRR-altered mHSPC, adding talazoparib to enzalutamide + ADT:

✅ Reduced risk of progression/death by 52% (HR 0.48)
📈 3-year rPFS: 77% vs 56%
⏳ OS trend favors combination (HR 0.77), but immature.
⚠️ More anemia (Grade ≥3: 51%).

👉Potential new standard for a biomarker-selected population

@neerajaiims @urotoday @renalandurology @UrologyTimes @UroOnc @SUO_YUO @PCFnews

🔗https://t.co/YXCiIWPwqg

[Enrique Grande @drenriquegrande]

⚡️ INDIBLADE: ipi + nivo induction followed by chemoradiotherapy in stage II/III MIBC (n=50).

2-year bladder-intact EFS: 78%. 2-year OS: 96%.
ctDNA clearance after induction: strong predictor of BI-EFS (HR 8.3).

https://t.co/6UMfFOsuTF

#BladderCancer @NatureMedicine

[Katy Beckermann @katy_beckermann]

The ctDNA conversation in bladder cancer has changed. Assays work well enough now that the Think Tank breakout spent its time on the harder problem, building ctDNA into trials.

🔬 The clearest data came from trimodal therapy. After chemoradiation, ctDNA turned positive about 8 weeks before imaging caught progression. It flags distant recurrence and misses local, so it is a lead, not the whole picture.
🎯 Perioperative, the pitch is selection: who needs adjuvant therapy and who can be spared it, IMvigor-011 and Niagara teaching us
💊 On systemic therapy and in metastatic disease, serial testing to read response early.

Challenges of logistics: when to draw, which assay, how regulators are thinking of it as an early or surrogate endpoint. When do we react clinically is it a doubling time and slope of the curve rather than basic positivity?

Lots of great discussion from this expert panel!
@mouwlab @alantanmd @LauraBukavinaMD @BladderCancerUS #BladderCancer #ctDNA #GUonc #BCANTT26

[UroToday.com @urotoday]

Identifying biomarkers of response and mechanisms of resistance to enfortumab vedotin with and without pembrolizumab in metastatic #UrothelialCancer. Presentation by Aditi Gupta, MD @MSKCancerCenter. #BCANTT26 written coverage by @chavarriagaj @PSH_Urology. #ReadNow > https://t.co/8Y7bsdF78n @BladderCancerUS

[JOSPT Community @JOSPT]

Which exercises have been used in rehabilitation studies on #Athletes with #GroinPain and how well have those studies been reported 🤔

Our July #Review takes a look ➡️https://t.co/txLh2jfu2N

#yourJOSPT #Rehabilitation #Hip #Groin

[European Urology Oncology @EurUrolOncol]

➡️ One highlight from our latest issue you won't want to miss
https://t.co/nqkdU2OeaP

➡️ Diagnostic Accuracy of Liquid-Based Biomarkers for Detecting and Risk Stratifying Upper Tract Urothelial Cancers: A Diagnostic Test Systematic Review by the EAU Guidelines UTUC Panel by Bhavan Prasad Rai ...Alexandra Masson-Lecomte et al

➡️ Thank you to the authors for trusting EUO with your work!

@stingrai78

@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[Tom Powles @tompowles1]

Quality of life data from LITESPARK-22 #KCRS26 (pembro+belzutifan in adjuvant RCC). Three different tools (FKSI/EORTCQLQ30/GP5) show a temporary dip in global and physical/role function QOL while on therapy, which didn’t hit predefined clinically meaningful levels. This is consistent with the reversible belzutifan toxicity signal (fatigue/anaemia). There is a need to look at quality of life analysis in different ways @BethN01 @DrChoueiri @montypal @Annals_Oncology @OncoAlert

[Carlos Alvarez @duemed]

Very humbled to be part of this clinical trial.

Advancing on the management of #bladdercancer from Spain @HUCA_Asturias @astursalud

Many thanks to all the people involved in the trial and also patients and their families.

[Enrique Grande @drenriquegrande]

⚡️KEYNOTE-B15/EV-304 published in @NEJM: perioperative EV + pembrolizumab vs cisplatin-gemcitabine in cisplatin-eligible MIBC.

Significant improvements in EFS, OS and pCR. The perioperative standard now extends to all MIBC patients candidates for cystectomy.

https://t.co/vLWW1n3pqg

#BladderCancer